» Authors » Uwe Platzbecker

Uwe Platzbecker

Explore the profile of Uwe Platzbecker including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 507
Citations 11203
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Bischof L, Ussmann J, Platzbecker U, Jentzsch M, Franke G
Leuk Lymphoma . 2025 Mar; :1-14. PMID: 40072896
Despite the vast heterogeneity of myelodysplastic neoplasm (MDS), treatment options are limited and an allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative approach. While, subsequently, allo-HSCT is the...
2.
Gisriel S, Aakash F, Bennett J, Hasserjian R, Loghavi S, DeZern A, et al.
Arch Pathol Lab Med . 2025 Mar; PMID: 40059041
Context.—: Standardized bone marrow reporting specifically for myelodysplastic syndromes/neoplasms (MDS) is currently lacking in the literature and much needed in practice. Objective.—: To propose a standardized approach to MDS evaluation...
3.
Stasik S, Eckardt J, Rollig C, Baldus C, Platzbecker U, Serve H, et al.
Br J Haematol . 2025 Mar; PMID: 40041934
IKZF1 mutations are recurrent alterations in acute myeloid leukaemia (AML), and hotspot point mutation, N159S, has recently been associated with unique gene expression and adverse risk. To better understand the...
4.
Oliva E, Guo S, Lord-Bessen J, Yucel A, Latagliata R, Breccia M, et al.
Front Oncol . 2025 Feb; 15:1507854. PMID: 39990686
Background: Myelodysplastic neoplasms (MDS) are characterized by ineffective hematopoiesis, peripheral blood cytopenias, and an increased risk of progression to acute myeloid leukemia. One of the main treatment goals is improving...
5.
Braun T, Rade M, Merz M, Klepzig H, Grosse F, Fandrei D, et al.
Nat Med . 2025 Feb; PMID: 39984633
Chimeric antigen receptor (CAR) T cells and bispecific T cell engagers have become integral components in the treatment of relapsed/refractory multiple myeloma. We report a 63-year-old male who received ciltacabtagene...
6.
Gurnari C, Robin M, Ades L, Aljurf M, Almeida A, Duarte F, et al.
Blood . 2025 Feb; PMID: 39970324
For patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis. Biologic-assignment...
7.
Tometten M, Beier F, Kirschner M, Schumacher Y, Walter J, Vieri M, et al.
Blood Adv . 2025 Feb; PMID: 39938003
Pathogenic germline variants affecting proper telomere maintenance result in premature telomere shortening and cause telomere biology disorders (TBDs). While classical dyskeratosis congenita in children is rather well defined, late-onset ("cryptic")...
8.
Weissflog G, Ernst J, Esser P, Platzbecker U, Vucinic V, Mehnert-Theuerkauf A, et al.
J Behav Med . 2025 Feb; PMID: 39924603
Anxiety disorders and/or depressive disorders co-occurring with hematological cancer are an additional burden for patients. Experiential avoidance (EA; efforts to avoid negative emotions, thoughts, or memories) is an empirically evident...
9.
Platzbecker U, Larson R, Gurbuxani S
Hemasphere . 2025 Feb; 9(2):e70083. PMID: 39897085
As a consequence of rapidly developing genetic technologies and advances in the understanding of the pathogenesis of acute myeloid leukemia (AML), the classification of AML has moved gradually from a...
10.
Rollo C, Pancotti C, Sartori F, Caranzano I, DAmico S, Carota L, et al.
Comput Methods Programs Biomed . 2025 Jan; 261:108605. PMID: 39874934
Background And Objectives: Several computational pipelines for biomedical data have been proposed to stratify patients and to predict their prognosis through survival analysis. However, these analyses are usually performed independently,...